BioCryst Pharmaceuticals (BCRX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 02/14/23
BioCryst to Present New ORLADEYO® (berotralstat) Data at 2023 American Academy of Allergy, Asthma & Immunology Annual MeetingGlobeNewsWire • 02/03/23
BioCryst Begins Enrollment in Pivotal APeX-P Trial Evaluating ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary AngioedemaGlobeNewsWire • 01/26/23
BioCryst Selects Swixx BioPharma as Commercial Partner for ORLADEYO® (berotralstat) in Central and Eastern EuropeGlobeNewsWire • 01/23/23
BioCryst Announces Preliminary Full Year 2022 ORLADEYO® (berotralstat) Net Revenue and Provides Full Year 2023 ORLADEYO Net Revenue GuidanceGlobeNewsWire • 01/09/23
BioCryst Reports Initial Clinical Data with Oral Factor D Inhibitor BCX10013 Supporting Development as a Once-daily Treatment for Complement-mediated DiseasesGlobeNewsWire • 01/09/23
Wall Street Analysts Predict a 48% Upside in BioCryst (BCRX): Here's What You Should KnowZacks Investment Research • 01/04/23
BioCryst Discontinues Development of BCX9930 and Shifts Focus to Potential Once-daily, Oral Factor D Inhibitor, BCX10013GlobeNewsWire • 12/15/22
BioCryst Announces Approval of ORLADEYO® (berotralstat) by the Israeli Ministry of HealthGlobeNewsWire • 11/28/22
BioCryst Presents Real-World Data Showing Rapid and Sustained HAE Attack Rate Reduction After Beginning ORLADEYO® (berotralstat), Regardless of Prior Prophylactic TherapyGlobeNewsWire • 11/10/22
BioCryst Reports Third Quarter 2022 Financial Results and Upcoming Key MilestonesGlobeNewsWire • 11/01/22
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?Investors Business Daily • 10/20/22